Lupin bags USFDA okay for seizure treatment drug Rufinamide
Rufinamide Tablets will be manufactured at Lupin’s facility in Goa, India.;
Advertisement
Mumbai: Global pharma major, Lupin Limited, today announced that the company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Rufinamide Tablets USP, 100 mg, 200 mg, and 400 mg.
The product is a generic equivalent of Banzel Tablets, 100 mg, 200 mg, and 400 mg, of Eisai Inc.
Rufinamide is used with other medications to control seizures in patients who have Lennox-Gastaut syndrome. Rufinamide belongs to a class of drugs known as Anticonvulsants.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.